Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Accepts First Diabetes Drug Onto PRIME

Hemophilia A Gene Therapy & DLBCL CAR-T Also Make The Grade

Executive Summary

Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.

You may also be interested in...



Could A Type 1 Diabetes Immunotherapy Be In Reach?

Promising data from the likes of Provention Bio and Diamyd Medical suggest that treatment for the autoimmune disorder type 1 diabetes could soon move beyond insulin.

EU Fast-Track Success For BioMarin’s Valrox But Not For Amarin’s Vascepa

Just one of four accelerated assessment requests that were decided on at the European Medicines Agency this month is known to have been granted – for BioMarin’s Valrox. There was rejection for Amarin; Roche and Orchard are keeping the outcomes to themselves.

T1D Silver Bullet? Provention Bio Soars On Hopes Teplizumab Is Type 1 Diabetes Game Changer

Shares in Provention Bio were pushed sharply higher on Monday after news that a two-week course of its experimental immunotherapy teplizumab dramatically reduced type 1 diabetes diagnosis rates in people at high risk for the disease.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel